German researchers report the case of a patient with Lambert-Eaton syndrome (or LEMS, a presynaptic disorder of the neuromuscular junction very often of paraneoplastic origin) who benefited from an innovative therapy:
- the patient had an idiopathic form of LEMS,
- autologous anti-CD19 CAR-T cells were administered, resulting in selective depletion of B lymphocytes,
- positive results were observed both clinically (very significant improvement in walking perimeter) and biologically (significant drop in anti-CCVD (voltage-dependent calcium channel) autoantibodies),
- the beneficial effect appeared to be long-lasting, with good tolerability.
This work is an example of the growing importance of CAR-T cells as a therapeutic tool of the future.
